StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ISPC yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $4.22 | $3.93 | -6.87% | 0.2M |
| 05-19 | $3.90 | $3.67 | -5.90% | 0.1M |
| 05-20 | $3.56 | $3.40 | -4.49% | 0.2M |
| 05-21 | $3.37 | $3.57 | +5.93% | 0.1M |
| 05-22 | $3.59 | $3.45 | -3.90% | 0.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 | Q1 2024 2024-03-31 | Annual 2023 2023-12-31 |
|---|---|---|---|---|
Revenue | $7.82M | $5.15M | $2.29M | $9.93M |
Operating Income | $-6.89M | $-5.18M | $-3.00M | $-11.17M |
Net Income | $-6.45M | $-2.11M | $-2.90M | $-11.10M |
EPS (Diluted) | $-11.30 | $-9.79 | $-6.36 | $-24.55 |
Total Assets | $11.26M | $11.90M | $12.51M | $15.82M |
Total Liabilities | $6.55M | $5.81M | $5.70M | $6.08M |
Cash & Equivalents | $1.75M | $2.15M | $2.09M | $2.34M |
Free Cash Flow OCF − CapEx | $-4.71M | $-3.62M | $-2.08M | $-5.83M |
Shares Outstanding | 829.82K | 13.10M | 9.47M | 454.17K |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.